Indies Pharma Jamaica Limited

What it is

Indies Pharma distributes more than 150 prescription and over-the-counter generic drugs under the Bioprist brand, serving customers across all 14 parishes of Jamaica — including over 400 pharmacies, public and private hospitals, and government agencies such as the National Health Fund. It also operates Trident Pharmacy, a full-service retail chemist in Montego Bay, which is one of its own top customers.

The company is vertically integrated, offering consulting, regulatory, and intellectual-property services to overseas drug manufacturers, and has moved beyond promoting third-party brands to building its own brand equity through secured trademarks. It holds more than 450 drug registrations across 23 therapeutic segments in Jamaica.

Who owns it

Bioprist Group — a fully family-owned holding company controlled by Dr. Guna Muppuri and his wife Vishnu — holds approximately 80% of Indies Pharma Jamaica Ltd. The holding was structured as “an inter-company movement from personal shareholding to the parent entity at Bioprist,” in 2019, consolidating family control under a single vehicle.

The remaining roughly 20% of shares trade freely on the JSE Junior Market, meaning public investors hold a relatively thin float in a tightly held company. A CFO is not disclosed in available sources; Mrs. Vishnu Muppuri serves as an executive director and board member.

Who runs it

Dr. Guna S. Muppuri — founder, President and CEO — is an Indian-born physician who migrated to Jamaica in 1992 as a medical intern, and went on to observe first-hand how ordinary Jamaicans struggled to afford prescription drugs.

In 2005, at age 35, he became the principal founder and CEO of Indies Pharma Jamaica Limited.

He has received India’s highest honour for non-resident Indians, the Pravasi Bharatiya Samman (2019), and was appointed an Officer of the Order of Distinction by the Government of Jamaica (2021) for contributions to medicine and philanthropy. Prof.

Trevor McCartney serves as independent board chairman, with Mr. Kevin Donaldson and Mr. Lissant Mitchell as independent board members.

The money, in plain words

In the financial year ended 31 October 2025, revenue declined 2.8% to JMD 1.13 billion (US$7.2 m), while net profit fell to JMD 181.3 million (US$1.16 m) — down from JMD 221.2 million a year earlier — though gross profit held steady at JMD 775.5 million (US$4.95 m). The company kept about 16 cents of profit from every Jamaican dollar of sales — a net profit margin of 16.0% (our calculation) — healthy for a small-island distributor, though the thinnest it has been in several years.

For every dollar owners have invested, the business earns back about 16.5 cents a year — a return on equity of 16.5%, solid but below the 19–42% range it ran in earlier years. The balance sheet carries JMD 843 million (US$5.4 m) of debt against JMD 215 million (US$1.4 m) of cash, a net debt position of JMD 627 million (US$4.0 m) — a legacy of a bond raise in 2020 that funded expansion.

The company has no written dividend policy, but has paid an average of JMD 0.11 per share annually since it listed in 2018.

What it is doing now

The most significant recent development is Indies Pharma’s entry into the US market: it secured US$405,000 (about JMD 63 million) in its first commercial sale of Regadenoson Injection — a cardiovascular generic drug — after winning US FDA approval, the first such approval ever achieved by a Caribbean company. The drug is manufactured under contract by a company in India.

US export revenue from Regadenoson began flowing in March 2025, with wider American distribution expected to ramp up and provide a foreign-currency hedge against domestic supply bottlenecks. At home, growth has been held back by delays in regulatory approval for new generic drugs the company wants to distribute locally.

What to watch

• US ramp-up: A former board member has been appointed as special adviser for US operations and acquisitions, and the company plans to raise additional capital to acquire more drug licences for the American market.
• Domestic approvals: Delays stem from a change in regulatory requirements that affected the application process for drug approvals — clearing that backlog would be the fastest route back to the 20% growth the CEO has pledged.
• Debt reduction: With net debt equal to roughly 55% of annual sales, management’s stated goal is to grow the capital base before pressing into further drug development; watch whether the US revenue stream accelerates that deleveraging.
• Thin float: With ~80% of shares locked inside the Bioprist family, the free-float is small and trading is light — price moves can be sharp on modest volume.

This is news, not investment advice.